- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ironwood Pharmaceuticals Inc (IRWD)
Ironwood Pharmaceuticals Inc stock price live, this page displays NASDAQ IRWD stock exchange data. View the IRWD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ironwood Pharmaceuticals Inc real time stock price chart below.
What Is the Ironwood Pharmaceuticals Inc Stock Price Today?
The Ironwood Pharmaceuticals Inc stock price today is 0.84.
What Is the Stock Symbol for Ironwood Pharmaceuticals Inc?
The stock symbol for Ironwood Pharmaceuticals Inc is ""IRWD.""
What Stock Exchange Does Ironwood Pharmaceuticals Inc Trade On?
Ironwood Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Ironwood Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Ironwood Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IRWD quote. (ISIN: US46333X1081)
What Is the Ironwood Pharmaceuticals Inc Stock Price Today?
The Ironwood Pharmaceuticals Inc stock price today is 0.84.
What Is the Stock Symbol for Ironwood Pharmaceuticals Inc?
The stock symbol for Ironwood Pharmaceuticals Inc is ""IRWD.""
What Stock Exchange Does Ironwood Pharmaceuticals Inc Trade On?
Ironwood Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Ironwood Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Ironwood Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IRWD quote. (ISIN: US46333X1081)
0.84
-0.06(-6.69%)
Closed·
After Hours
0.83-0.01(-0.99%)
·
Fair Value
An estimate of a Ironwood's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.81
0.91
52 wk Range
0.53
5.21
IRWD Scorecard
Full Analysis
Net income is expected to grow this year
IRWD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Ironwood's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.810.91
52 wk Range
0.535.21
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IRWD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ironwood's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
0.95
Upside
+13.10%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Form 8K Ironwood Pharmaceuticals Inc For: 10 July
- Investing.com
- Form 8K Ironwood Pharmaceuticals Inc For: 10 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Ironwood Pharmaceuticals Inc Company Profile
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals Inc SWOT Analysis
Apraglutide's Promise | Explore how Ironwood's Phase III study results for apraglutide in SBS-IF patients are reshaping the company's market outlook and potential leadership in treatment |
Market Positioning | Delve into apraglutide's unique attributes, including once-weekly dosing and broad efficacy, positioning it as a potential best-in-class therapy for SBS-IF |
Financial Landscape | Analyst price targets range from $5 to $23, with Ironwood's market cap at $550.5M. InvestingPro data indicates strong liquidity with a 3.62 current ratio |
Strategic Outlook | Learn about Ironwood's upcoming catalysts, including the NDA submission for apraglutide and Phase 2 results for CNP-104, driving potential growth opportunities |
Ironwood Pharmaceuticals Inc Earnings Call Summary for Q3/2024
- LINZESS prescription demand up 13% YoY, but U.S. net sales down 19% to $226M due to pricing pressures
- Q3 revenue: $92M, GAAP net income: $4M, Adjusted EBITDA: $26M; NDA for apraglutide planned for Q1 2025
- 2024 guidance: LINZESS U.S. net sales $900M-$950M, total revenue $350M-$375M, Adjusted EBITDA >$75M
- Debt maturity extended to Dec 2028; $88M cash on hand plus $50M liquidity boost; $25M revolving credit repaid
- Focus on LINZESS profit optimization and apraglutide development; 2025 guidance to be provided next year
Last Updated: 08/11/2024, 21:00
Read Full TranscriptCompare IRWD to Peers and Sector
Metrics to compare | IRWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIRWDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.2x | −4.2x | −0.5x | |
PEG Ratio | 0.09 | −0.10 | 0.00 | |
Price/Book | −0.4x | 1.7x | 2.6x | |
Price / LTM Sales | 0.4x | 7.7x | 3.3x | |
Upside (Analyst Target) | 19.0% | 218.2% | 42.9% | |
Fair Value Upside | Unlock | 10.4% | 6.2% | Unlock |
Analyst Ratings
0 Buy
5 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.95
(+13.10% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
0.14 / 0.03
Revenue / Forecast
85.24M / 62.00M
People Also Watch
FAQ
What Stock Exchange Does Ironwood Trade On?
Ironwood is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Ironwood?
The stock symbol for Ironwood is "IRWD."
What Is the Ironwood Market Cap?
As of today, Ironwood market cap is 135.33M.
What Is Ironwood's Earnings Per Share (TTM)?
The Ironwood EPS (TTM) is -0.05.
When Is the Next Ironwood Earnings Date?
Ironwood will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is IRWD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Ironwood Stock Split?
Ironwood has split 0 times.
How Many Employees Does Ironwood Have?
Ironwood has 253 employees.
What is the current trading status of Ironwood (IRWD)?
As of 12 Aug 2025, Ironwood (IRWD) is trading at a price of 0.84, with a previous close of 0.84. The stock has fluctuated within a day range of 0.81 to 0.91, while its 52-week range spans from 0.53 to 5.21.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.